A recently published modified version predicting response to neoadjuvant CRT in localized rectal cancer, the “biopsy-adapted immunoscore”, is solely based on CD3+ and CD8+ T cell density in the tumor region [39]. The gene discussed is CD8A; the disease is rectal cancer.